NASDAQ:ACET
Adicet Bio Inc Stock News
$1.81
-0.0650 (-3.47%)
At Close: Apr 25, 2024
3 Biotech Stocks That Could Make You Richer in February (and Beyond)
06:05am, Saturday, 05'th Feb 2022
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
3 Biotech Stocks That Could Double in 2022
06:04am, Monday, 03'rd Jan 2022
They're risky. But with the high risk comes the potential for high rewards.
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate
09:09am, Wednesday, 08'th Dec 2021
Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer price represents a discount of alm
Adicet Bio Stock (ACET): Why The Price Surged Today
07:43am, Monday, 06'th Dec 2021
The stock price of Adicet Bio Inc (NASDAQ: ACET) increased by over 40% pre-market today. This is why it happened.
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma
07:00am, Monday, 29'th Nov 2021
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates
07:05pm, Wednesday, 10'th Nov 2021
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
04:10pm, Tuesday, 12'th Oct 2021
MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therap
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
07:00am, Monday, 04'th Oct 2021
MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therap
Adicet Bio to Participate in Upcoming Investor Conferences
04:53pm, Thursday, 02'nd Sep 2021
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
07:19pm, Thursday, 12'th Aug 2021
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio to Participate in Upcoming Investor Conferences
07:00am, Monday, 02'nd Aug 2021
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other d
Adicet Bio Added to the Russell 2000® Index
07:00am, Monday, 28'th Jun 2021
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Moving Average Crossover Alert: Adicet Bio (ACET)
07:31am, Tuesday, 01'st Jun 2021
Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Adicet Bio to Participate in Upcoming Investor Conferences
04:10pm, Tuesday, 18'th May 2021
MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other di
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
07:01am, Monday, 17'th May 2021
MENLO PARK, Calif. and BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapi